Nvidia Corp
$4.49T- Market cap
- $4.49T
- Debt
- +$8.47B
- Cash
- −$10.61B
Capital structure 100% equity / 0% debt · EV / Revenue 20.80x · EV proxy / EBITDA proxy 33.72x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NVDA stock price vs CI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CI's multiple
Needs CI P/E.
Implied fair value · at NVDA's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 100% equity / 0% debt · EV / Revenue 20.80x · EV proxy / EBITDA proxy 33.72x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NVIDIA CORP · implied price per share
Bear
$43.09
Base
$52.57
Bull
$59.95
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ADVANCED MICRO DEVICES INC
NVDA vs AMD
INTEL CORP
NVDA vs INTC
TEXAS INSTRUMENTS INC
NVDA vs TXN
Broadcom Inc.
NVDA vs AVGO
QUALCOMM INC/DE
NVDA vs QCOM
MICROCHIP TECHNOLOGY INC
NVDA vs MCHP
UNITEDHEALTH GROUP INC
NVDA vs UNH
CVS HEALTH Corp
NVDA vs CVS
HUMANA INC
NVDA vs HUM
CENTENE CORP
NVDA vs CNC
WEST PHARMACEUTICAL SERVICES INC
NVDA vs WST
BAXTER INTERNATIONAL INC
NVDA vs BAX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NVDA can sustain its 65.5% revenue growth and 60.4% operating margin for longer than the market expects, then hold or accumulate selectively because the business quality is exceptional; otherwise, trim or avoid because the current 38.1x P/E and 22.5x P/S already price in a great deal of that strength.
NVDA trades at $200.75 versus an implied P/E value of $61.65, implying 69.3% downside and a large valuation premium that is hard to reconcile with the provided CI and DCF ranges. The gap is driven by NVDA's much higher P/E and sales multiple than CI, even though NVDA also has much stronger growth and profitability.
Supporting Metrics